Wyss InstituteImmunotherapy – Wyss Institute

Wyss Institute’s iNodes team receives ARPA-H Sprint for Women’s Health award to advance the first implantable immune organs to treat ovarian cancer

Jessica Leff — Tue, 12 Nov 2024 14:58:41 +0000

By Benjamin Boettner (BOSTON) — Ovarian cancer is more deadly than any other type of female reproductive organ cancer. It is estimated that in 2024, in the U.S. alone, more than 12,000 women will die from the disease because available therapies are not effective. To help overcome this striking deficit in women’s health, ARPA-H has selected a team at the Wyss Institute at Harvard University as…

Source

Kwasi Adu-Berchie named 2024 STAT Wunderkind

Jessica Leff — Wed, 16 Oct 2024 14:11:12 +0000

By Lindsay Brownell (BOSTON) – The Wyss Institute is thrilled to announce that Kwasi Adu-Berchie, Ph.D., a member of the Wyss’ Advanced Technology Team working in Immuno-Materials Platform led by Core Faculty member Dave Mooney, Ph.D., has been named a 2024 STAT Wunderkind by STAT News. The Wunderkinds awards are given annually by STAT News to the next generation of scientific superstars who…

Source

Attivare licenses Wyss Institute’s immune-modulating biomaterial technology to advance immunotherapies

Jessica Leff — Wed, 02 Oct 2024 13:20:13 +0000

By Benjamin Boettner (BOSTON) — Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Attivare Therapeutics Inc. announced that Attivare has licensed a portfolio of immune-modulating biomaterial technologies from Harvard University that was created at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences (SEAS)…

Source

Eliz Amar Lewis on Using Many Tools to Fight a Sophisticated Disease

Jessica Leff — Tue, 24 Sep 2024 14:50:19 +0000

The Humans of the Wyss (HOW) series features members of the Wyss community discussing their work, the influences that shape them as professionals, and their collaborations at the Wyss Institute and beyond. Eliz Amar Lewis has always been fascinated by biology. But when she saw her grandmother bravely battle breast cancer, she was inspired to use her passion to develop a smart and sophisticated…

Source

Wyss Institute team selected by DARPA-SHIELD program to develop first-of-its-kind biologically engineered broad-spectrum antimicrobial therapeutic

Jessica Leff — Mon, 16 Sep 2024 13:25:50 +0000

By Benjamin Boettner (BOSTON) — Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University received a contract for up to $12M from the Defense Advanced Research Projects Agency (DARPA)’s new SHIELD program. The SHIELD (Synthetic Hemo-technologies to Locate and Disinfect) program aims to develop a prophylactic treatment that can be broadly administered to…

Source

Vinny Chandran Suja on Making Backpacks More Reliable and Predictable

Jessica Leff — Tue, 20 Aug 2024 13:10:41 +0000

The Humans of the Wyss (HOW) series features members of the Wyss community discussing their work, the influences that shape them as professionals, and their collaborations at the Wyss Institute and beyond. As a kid, Vinny Chandran Suja had no interest in biology. Instead, his math and science acumen led him to pursue degrees in mechanical and chemical engineering, studying non-living systems.

Source

Wyss Institute promotes Natalie Artzi to its Core Faculty and appoints Di Feng as an Associate Faculty member

Jessica Leff — Mon, 12 Aug 2024 13:15:25 +0000

By Benjamin Boettner (BOSTON) — Natalie Artzi, Ph.D., joined the ranks of the Wyss Institute’s now 12 Core Faculty members after only two years as an Associate Faculty member. Artzi’s promotion reflects her exceptional commitment to the Institute’s mission and the deep engagements and collaborations she has initiated within its technology development community. The Wyss Institute also warmly…

Source

Wyss Institute Research Collaboration Awarded ARPA-H Agreement to Develop Disease-Agnostic Immunotherapeutic RNA Platform

Jessica Leff — Mon, 15 Jul 2024 14:55:26 +0000

By Benjamin Boettner With the award for up to $27M from the Advanced Research Projects Agency for Health (ARPA-H), a collaborative research project at the Wyss Institute for Biologically Inspired Engineering at Harvard University will advance a disease-agnostic novel RNA therapeutic with the potential to treat diverse diseases, and to be effectively and rapidly deployable.

Source

Boosting CAR-T cell therapies from under the skin

Jessica Leff — Wed, 12 Jun 2024 13:15:07 +0000

By Benjamin Boettner (BOSTON) — CAR-T cell therapies are transforming the treatment of previously incurable blood cancers. Six approved CAR-T products have been administered to more than 20,000 people, and more than 500 clinical trials are underway. However, according to a recent study out of the Massachusetts General Hospital, among 100 patients suffering from lymphomas, myelomas or B-cell…

Source

The Wyss Institute’s 2024-2025 Validation Projects

Jessica Leff — Wed, 29 May 2024 14:55:23 +0000

Every year the Wyss Institute names a class of Validation Projects whose teams receive dedicated funding, business development support, and other resources to advance their promising technologies towards commercialization. They also collaborate with key opinion leaders, investors, and potential customers to de-risk their innovations and speed their progress to the market. This year…

Source